Four faculty members have received 2019-2020 Applied Research & Development (ARaD) Awards from the Center for Biotechnology at Stony Brook University. The ARaD program helps bridge the gap between early-stage technology discovery and development capabilities of the academic community, and the later-stage commercial development interests of the bioscience industry.
The winners include:
Dr. Wei Lin, Associate Professor, Biomedical Engineering, “Temporary Pacemaker,” with Avery Biomedical Devices
Dr. Srinivas Pentyala, Professor and Director of Translational Research, Anesthesiology, Stony Brook Medicine, “c-VACNT Material Bio-interaction Studies,” with CVD Equipment Corporation
Dr. Sanford Simon, Professor, Biochemistry & Cell Biology and Pathology, “Evaluation of Hydrogenated Curcumins as Skin Brightening Agents with Novel Antimelanogenic and Antioxidant,” with BioCogent, LLC
Dr. Thomas Zimmerman, Assistant Professor and Director, Division of Laboratory Animal Resources, Stony Brook University; Attending Veterinarian, Brookhaven National Laboratory; Attending Veterinarian, Cold Spring Harbor Laboratory, “Evaluation of Small Molecule Bax Activators in Mouse Models of Lung Cancer,” with PHD Biosciences
“The Center for Biotechnology is thrilled to be able to continue to collaborate with New York State companies to help them develop commercially promising technologies that will lead to strategic partnerships, investment, corporate revenues, and job creation,” said Diane Fabel, Director of Operations for the Center for Biotechnology. “The projects supported by this year’s Applied Research and Development awards exemplify the innovative science happening all around us both in our academic institutions and bioscience companies. The Center for Biotechnology is excited to be an engine promoting interactions between the two to help fuel the overall bioscience ecosystem in the region.”
The ARaD program provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and New York State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.
Projects supported this year include the further development of an Intensive Care Unit temporary pacemaker, a novel material platform to improve extracorporeal membrane oxygenation (ECMOs) in heart-lung machines, further development of skin brightening agents, and a novel therapeutic to treat lung cancer.
“Through our participation in the Applied Research and Development Program at the Center for Biotechnology, we have been able to access the expertise of Dr. Wei Lin in the Department of Biomedical Engineering to collaborate on strategic research projects,” said Linda Towler, CEO of Avery Biomedical Devices, a global leader in high-reliability diaphragm pacemakers. “This research and development collaboration has allowed us to considerably accelerate our product development, and we expect it to generate significant new revenue for the company downstream.”
The ARaD Program is part of a suite of programs and services provided by the Center for Biotechnology focused on accelerating the development of biomedical technologies to have a positive impact on human health and society.
About the Center for Biotechnology
Established in 1983, the Center for Biotechnology (CFB) at Stony Brook University is an Empire State Development Division of Science, Technology and Innovation (NYSTAR) Center for Advanced Technology. The CFB serves as an important catalyst in the development of new biomedical technologies and emerging companies in New York State. Through groundbreaking initiatives, the Center supports technology commercialization and company formation by bridging the gap between discovery and commercial success, and by training the next generation of biomedical leaders. The CFB also supports New York’s biotechnology industry by providing access to scientific and business expertise and creating strategic infrastructure that promotes the growth of the life sciences industry in the State. The CFB has contributed to the development of more than a dozen FDA approved products including ReoPro®, Xiaflex®, Oracea®, Cavistat®, V3D®-Colon Virtual Colonoscopy and Exogen® Bone Healing System, among others. It has also helped launch 18 companies.
Add comment